The mRNAs of specific-cGMP PDEs such as PDE5 have been shown to be increased in various cancers; thus, the inhibitors of this enzyme could be suitable therapeutic candidates for breast cancer[19]. The gene discussed is PDE5A; the disease is breast carcinoma.